210 results on '"Calbacho, María"'
Search Results
2. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
- Author
-
Martín-Vallejo, Francisco Javier, Zdziarski, Przemyslaw, Zarrinfer, Hossein, Wittig, Jana, Win, Sein, Wai-Man, Vivien, Víšek, Benjamín, Vinh, Donald C., Vehreschild, Maria, Varricchio, Gina, Tsirigotis, Panagiotis, Torres-Tienza, Ana, Tanase, Alina Daniela, Tafuri, Agostino, Stamouli, Maria, Sramek, Jiří, Soussain, Carole, Shirinova, Ayten, Schubert, Jörg, Schalk, Enrico, Salehi, Mohammad Reza, Saleh, Modar, Rosati, Giorgio, Roldán, Elisa, Reizine, Florian, Rêgo, Mayara, Regalado-Artamendi, Isabel, Popova, Marina, Pinto, Fernando, Philippe, Laure, Orth, Hans Martin, Ommen, Hans-Beier, Obr, Aleš, Núñez-Martín-Buitrago, Lucía, Noël, Nicolas, Neuhann, Julia, Nadali, Gianpaolo, Nacov, Julia A., Munhoz Alburquerque, Ana M., Mitra, Maria Enza, Mikulska, Malgorzata, Mellinghoff, Sibylle, Mechtel, Ben, Martín-González, Juan-Alberto, Malak, Sandra, Loureiro-Amigo, Jorge, Lorenzo De La Peña, Lisset, Liberti, Giulia, Landau, Marianne, Lacej, Ira, Kolditz, Martin, Kho, Chi Shan, Khedr, Reham Abdelaziz, Karthaus, Meinolf, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Izuzquiza, Macarena, Hoell-Neugebauer, Baerbel, Herbrecht, Raoul, Heath, Christopher H., Guolo, Fabio, Grothe, Jan, Giordano, Antonio, Gerasymchuk, Sergey, García-Sanz, Ramón, García-Poutón, Nicole, Funke, Vaneuza Araújo Moreira, Fung, Monica, Flasshove, Charlotte, Fianchi, Luana, Essame, Jenna, Egger, Matthias, Drenou, Bernard, Dragonetti, Giulia, Desole, Maximilian, Della Pepa, Roberta, Deau Fischer, Bénédicte, De Kort, Elizabeth, De Cabo, Erik, Danion, François, Daguindau, Etienne, Cushion, Tania, Cremer, Louise, Criscuolo, Marianna, Cordini, Gregorio, Cingolani, Antonella, Ciceri, Fabio, Chowdhury, Fazle Rabbi, Chelysheva, Ekaterina, Chauchet, Adrien, Chai, Louis Yi Ann, Ceesay, M. Mansour, Busch, Elena, Brehon, Mathias, Borducchi, Davimar M.M., Booth, Stephen, Bologna, Serge, Berg Venemyr, Caroline, Bailén-Almorox, Rebeca, Antoniadou, Anastasia, Anastasopoulou, Amalia N., Altuntaş, Fevzi, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Weinbergerová, Barbora, Itri, Federico, Dávila-Valls, Julio, Martín-Pérez, Sonia, Glenthøj, Andreas, Hersby, Ditte Stampe, Gomes Da Silva, Maria, Nunes Rodrigues, Raquel, López-García, Alberto, Córdoba, Raúl, Bilgin, Yavuz M., Falces-Romero, Iker, El-Ashwah, Shaimaa, Emarah, Ziad, Besson, Caroline, Kohn, Milena, Van Doesum, Jaap, Ammatuna, Emanuele, Marchetti, Monia, Labrador, Jorge, Zambrotta, Giovanni Paolo Maria, Verga, Luisa, Jaksic, Ozren, Nucci, Marcio, Piukovics, Klára, Cabirta-Touzón, Alba, Jiménez, Moraima, Arellano, Elena, Espigado, Ildefonso, Blennow, Ola, Nordlander, Anna, Meers, Stef, Vian Praet, Jens, Aiello, Tommaso Francesco, Garcia-Vidal, Carolina, Fracchiolla, Nicola S., Sciumè, Mariarita, Seval, Guldane Cengiz, Žák, Pavel, Buquicchio, Caterina, Tascini, Carlo, Gräfe, Stefanie K., Schönlein, Martin, Adžić-VUKIČEVIĆ, Tatjana, Bonuomo, Valentina, Cattaneo, Chiara, Nizamuddin, Summiya, Čerňan, Martin, Plantefeve, Gaëtan, Prin, Romane, Szotkovski, Tomas, Collins, Graham P., Dargenio, Michelina, Petzer, Verena, Wolf, Dominik, Čolović, Natasha, Prezioso, Lucia, Valković, Toni, Passamonti, Francesco, Méndez, Gustavo-Adolfo, Sili, Uluhan, Vena, Antonio, Bavastro, Martina, Limongelli, Alessandro, Duarte, Rafael F., Ledoux, Marie-Pierre, Cvetanoski, Milche, Stojanoski, Zlate, Machado, Marina, Batinić, Josip, Magliano, Gabriele, Biernat, Monika M., Pantić, Nikola, Poulsen, Christian Bjørn, Cuccaro, Annarosa, Del Principe, Maria Ilaria, Kulasekararaj, Austin, Ormazabal-Vélez, Irati, Busca, Alessandro, Demirkan, Fatih, Ijaz, Marriyam, Klimko, Nikolai, Stoma, Igor, Khostelidi, Sofya, Fernández, Noemí, Omrani, Ali S., Bergantim, Rui, De Jonge, Nick, Fouquet, Guillemette, Navrátil, Milan, Abu-Zeinah, Ghaith, Samarkos, Michail, Maertens, Johan, De Ramón, Cristina, Guidetti, Anna, Magyari, Ferenc, González-López, Tomás José, Lahmer, Tobias, Finizio, Olimpia, Ali, Natasha, Pinczés, László Imre, Lavilla-Rubira, Esperanza, Romano, Alessandra, Merelli, Maria, Delia, Mario, Calbacho, Maria, Meletiadis, Joseph, Antić, Darko, Hernández-Rivas, José-Ángel, Marques De Almeida, Joyce, Al-Khabori, Murtadha, Hoenigl, Martin, Tisi, Maria Chiara, Khanna, Nina, Barać, Aleksandra, Eisa, Noha, Di Blasi, Roberta, Liévin, Raphaël, Miranda-Castillo, Carolina, Bahr, Nathan C., Lamure, Sylvain, Papa, Mario Virgilio, Yahya, Ayel, Aujayeb, Avinash, Novák, Jan, Erben, Nurettin, Fernández-Galán, María, Ribera-Santa Susana, José-María, Rinaldi, Ikhwan, Fazzi, Rita, Piedimonte, Monica, Duléry, Rémy, Gonzaga, Yung, Soto-Silva, Andrés, Sapienza, Giuseppe, Serris, Alexandra, Drgoňa, Ľuboš, Groh, Ana, Serrano, Laura, Gavriilaki, Eleni, Tragiannidis, Athanasios, Prattes, Juergen, Coppola, Nicola, Otašević, Vladimir, Mladenović, Miloš, Mitrović, Mirjana, Mišković, Bojana, Jindra, Pavel, Zompi, Sofia, Sacchi, Maria Vittoria, Krekeler, Carolin, Shumilov, Evgenii, Infante, Maria Stefania, García-Bordallo, Daniel, Çolak, Gökçe Melis, Mayer, Jiří, Nygaard, Marietta, Hanáková, Michaela, Ráčil, Zdeněk, Quattrone, Martina, Bonanni, Matteo, Koehler, Philipp, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio
- Published
- 2024
- Full Text
- View/download PDF
3. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
- Author
-
MARQUES DE ALMEIDA, Joyce, HERNÁNDEZ-RIVAS, José-Ángel, GUIDETTI, Anna, FINIZIO, Olimpia, STOJANOSKI, Zlate, CVETANOSKI, Milche, MELETIADIS, Joseph, DE JONGE, Nick, ANTIĆ, Darko, ALI, Natasha, TISI, Maria Chiara, SERRANO, Laura, PLANTEFEVE, Gaëtan, KHANNA, Nina, HOENIGL, Martin, ČERŇAN, Martin, MIRANDA-CASTILLO, Carolina, FERNÁNDEZ-GALÁN, María, SERRIS, Alexandra, ERBEN, Nurettin, DULÉRY, Rémy, AUJAYEB, Avinash, PAPA, Mario Virgilio, NOVÁK, Jan, DELIA, Mario, SAPIENZA, Giuseppe, REIZINE, Florian, OMRANI, Ali S., DI BLASI, Roberta, LAMURE, Sylvain, DRGOŇA, Ľuboš, COPPOLA, Nicola, BATINIĆ, Josip, AL-KHABORI, Murtadha, RIBERA-SANTA SUSANA, José-María, PIEDIMONTE, Monica, LOUREIRO-AMIGO, Jorge, FOUQUET, Guillemette, FAZZI, Rita, DANION, François, SCHUBERT, Jörg, HOELL-NEUGEBAUER, Baerbel, BAHR, Nathan C., YAHIA, Ayel Omar, TORRES-ATIENZA, Ana, RINALDI, Ikhwan, POPOVA, Marina, OMMEN, Hans-Beier, MITRA, Maria Enza, MIKULSKA, Malgorzata, LACEJ, Ira, KHOSTELIDI, Sofya, WIN, Sein, VINH, Donald, SALEH, Modar, PRATTES, Juergen, JINDRA, Pavel, GUOLO, Fabio, DELLA PEPA, Roberta, CHELYSHEVA, Ekaterina, ZDZIARSKI, Przemyslaw, WAI-MAN, Vivien, SOTO-SILVA, Andrés, ORTH, Hans Martin, MALAK, Sandra, LORENZO DE LA PEÑA, Lisset, KOLDITZ, Martin, Shan KHO, Chi, HEATH, Christopher H., GROH, Ana, GAVRIILAKI, Eleni, FUNG, Monica, EGGER, Matthias, DE KORT, Elizabeth, DE CABO, Erik, CUSHION, Tania, CHOWDHURY, Fazle Rabbi, CEESAY, M. Mansour, BREHON, Mathias, VARRICCHIO, Gina, TAFURI, Agostino, JIMÉNEZ-LORENZO, María-Josefa, KLIMKO, Nikolai, TSIRIGOTIS, Panagiotis, ANTONIADOU, Anastasia, VEHRESCHILD, Maria, Rossi, Giuseppe, Salmanton-García, Jon, Cattaneo, Chiara, Marchesi, Francesco, Dávila-Valls, Julio, Martín-Pérez, Sonia, Itri, Federico, López-García, Alberto, Glenthøj, Andreas, Gomes da Silva, Maria, Besson, Caroline, Marchetti, Monia, Weinbergerová, Barbora, Jaksic, Ozren, Jiménez, Moraima, Bilgin, Yavuz M., Van Doesum, Jaap, Farina, Francesca, Žák, Pavel, Verga, Luisa, Collins, Graham P., Bonuomo, Valentina, Van Praet, Jens, Nucci, Marcio, Meers, Stef, Espigado, Ildefonso, Fracchiolla, Nicola S., Valković, Toni, Poulsen, Christian Bjørn, Čolović, Natasha, Dragonetti, Giulia, Ledoux, Marie-Pierre, Tascini, Carlo, Buquicchio, Caterina, Blennow, Ola, Passamonti, Francesco, Machado, Marina, Labrador, Jorge, Duarte, Rafael F., Schönlein, Martin, Prezioso, Lucia, Falces-Romero, Iker, Kulasekararaj, Austin, Garcia-Vidal, Carolina, Fernández, Noemí, Abu-Zeinah, Ghaith, Ormazabal-Vélez, Irati, Adžić-Vukičević, Tatjana, Piukovics, Klára, Stoma, Igor, Cuccaro, Annarosa, Magliano, Gabriele, Szotkowski, Tomáš, González-López, Tomás-José, El-Ashwah, Shaimaa, Bergantim, Rui, Sili, Uluhan, Maertens, Johan, Demirkan, Fatih, De Ramón, Cristina, Petzer, Verena, Del Principe, Maria Ilaria, Navrátil, Milan, Dargenio, Michelina, Seval, Guldane Cengiz, Samarkos, Michail, Ráčil, Zdeněk, Pinczés, László Imre, Lahmer, Tobias, Busca, Alessandro, Méndez, Gustavo-Adolfo, Vena, Antonio, Biernat, Monika M., Merelli, Maria, Calbacho, Maria, Barać, Aleksandra, Bavastro, Martina, Limongelli, Alessandro, Ilhan, Osman, Wolf, Dominik, Çolak, Gökçe Melis, García-Sanz, Ramón, Emarah, Ziad, Mišković, Bojana, Gräfe, Stefanie K., Mladenović, Miloš, Aiello, Tommaso Francesco, Núñez-Martín-Buitrago, Lucía, Nordlander, Anna, Arellano, Elena, Zambrotta, Giovanni Paolo Maria, Ammatuna, Emanuele, Cabirta, Alba, Sacchi, Maria Vittoria, Nunes Rodrigues, Raquel, Hersby, Ditte Stampe, Hanakova, Michaela, Rahimli, Laman, Cordoba, Raul, Cornely, Oliver A., and Pagano, Livio
- Published
- 2023
- Full Text
- View/download PDF
4. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
- Author
-
Jiménez-Ubieto, Ana, Poza, María, Martin-Muñoz, Alejandro, Ruiz-Heredia, Yanira, Dorado, Sara, Figaredo, Gloria, Rosa-Rosa, Juan Manuel, Rodriguez, Antonia, Barcena, Carmen, Navamuel, Laura Parrilla, Carrillo, Jaime, Sanchez, Ricardo, Rufian, Laura, Juárez, Alexandra, Rodriguez, Margarita, Wang, Chongwu, de Toledo, Paula, Grande, Carlos, Mollejo, Manuela, Casado, Luis-Felipe, Calbacho, María, Baumann, Tycho, Rapado, Inmaculada, Gallardo, Miguel, Sarandeses, Pilar, Ayala, Rosa, Martínez-López, Joaquín, and Barrio, Santiago
- Published
- 2023
- Full Text
- View/download PDF
5. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
- Author
-
Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, van Praet, Jens, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José-Ángel, Glenthøj, Andreas, Fouquet, Guillemette, del Principe, Maria Ilaria, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Cordoba, Raul, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.
- Published
- 2023
- Full Text
- View/download PDF
6. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
- Author
-
van Doesum, Jaap A., Salmanton-García, Jon, Marchesi, Francesco, Di Blasi, Roberta, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Van Praet, Jens, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, De Ramón-Sánchez, Cristina, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almeida, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin, Hernández-Rivas, José-Ángel, Gomes da Silva, Maria, Fernández, Noemí, Espigado, Ildefonso, Drgoňa, Ľuboš, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, Maria, Blennow, Ola, Wolf, Dominik, van Anrooij, Bjorn, Nunes Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Liévin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie K., García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, van Meerten, Tom, Cornely, Oliver A., and Pagano, Livio
- Published
- 2023
- Full Text
- View/download PDF
7. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study
- Author
-
Tumbarello, Mario, Talento, Alida Fe, Ruiz, Alba C, Racil, Zdenek, Stoma, Igor, Calbacho, Maria, Van Wijngaerden, Eric, Henriques, Júlia, Jordan, Harriett, Ferroni, Valentina, Ozyurt, Ozlem Koyuncu, Milacek, Christopher, Krause, Robert, Zurl, Christoph, Backx, Matthijs, Li, Ang, Seufert, Raphael, Tomazin, Rok, Blankenheim, Yael, Dávila-Valls, Julio, García-Clemente, Paloma, Freiberger, Tomas, Buil, Jochem, Meis, Jacques F, Akyol, Deniz, Guegan, Hélène, Logan, Clare, Hoenigl, Martin, Salmanton-García, Jon, Egger, Matthias, Gangneux, Jean-Pierre, Bicanic, Tihana, Arikan-Akdagli, Sevtap, Alastruey-Izquierdo, Ana, Klimko, Nikolai, Barac, Aleksandra, Özenci, Volkan, Meijer, Eelco F J, Khanna, Nina, Bassetti, Matteo, Rautemaa-Richardson, Riina, Lagrou, Katrien, Adam, Kai-Manuel, Akalin, Emin Halis, Akova, Murat, Arsic Arsenijevic, Valentina, Aujayeb, Avinash, Blennow, Ola, Bretagne, Stéphane, Danion, François, Denis, Blandine, de Jonge, Nick Alexander, Desoubeaux, Guillaume, Drgona, Lubos, Erben, Nurettin, Gori, Andrea, García Rodríguez, Julio, Garcia-Vidal, Carolina, Giacobbe, Daniele Roberto, Goodman, Anna L, Hamal, Petr, Hammarström, Helena, Toscano, Cristina, Lanternier, Fanny, Lass-Flörl, Cornelia, Lockhart, Deborah E A, Longval, Thomas, Loughlin, Laura, Matos, Tadeja, Mikulska, Malgorzata, Narayanan, Manjusha, Martín-Pérez, Sonia, Prattes, Juergen, Rogers, Benedict, Rahimli, Laman, Ruiz, Maite, Roilides, Emmanuel, Samarkos, Michael, Scharmann, Ulrike, Sili, Uluhan, Sipahi, Oguz Resat, Sivakova, Alena, Steinmann, Joerg, Trauth, Janina, Turhan, Ozge, Van Praet, Jens, Vena, Antonio, White, P Lewis, Willinger, Birgit, Tortorano, Anna Maria, Arendrup, Maiken C, Koehler, Philipp, and Cornely, Oliver A
- Published
- 2023
- Full Text
- View/download PDF
8. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
- Author
-
Serrano, Laura, Ribera-Santa Susana, José-María, Meletiadis, Joseph, Tsirigotis, Panagiotis, Coppola, Nicola, Mikulska, Malgorzata, Erben, Nurettin, Besson, Caroline, Merelli, Maria, González-López, Tomás-José, Loureiro-Amigo, Jorge, García-Vidal, Carolina, Kort, Elizabeth de, Cuccaro, Annarosa, Zompi, Sofia, Reizine, Florian, Finizio, Olimpia, Duléry, Rémy, Calbacho, Maria, Abu-Zeinah, Ghaith, Malak, Sandra, Zdziarski, Przemyslaw, Varrichio, Gina, Tragiannidis, Athanasios, Plantefeve, Gaëtan, Duarte, Rafael, Danion, François, Tisi, Maria Chiara, Sakellari, Ioanna, Karthaus, Meinholf, Groh, Ana, Fung, Monica, Emarah, Ziad, Coronel-Ayala, Omar-Francisco, Ann Chai, Louis Yi, Brehon, Mathias, Bonuomo, Valentina, Wolf, Dominik, Wittig, Jana, Vehreschild, Maria, Papa, Mario Virgilio, Neuhann, Julia, Jiménez-Lorenzo, María-Josefa, Grothe, Jan, Gavriilaki, Eleni, García-Sanz, Ramón, García-Poutón, Nicole, El-Ashwah, Shaimaa Saber, Eggerer, Matthias, Cordoba, Raul, Çolak, Gökçe Melis, Arellano, Elena, Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Blennow, Ola, Gomes da Silva, Maria, Glenthøj, Andreas, van Doesum, Jaap, Bilgin, Yavuz M., López-García, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, van Praet, Jens, Jaksic, Ozren, Valković, Toni, Falces-Romero, Iker, Martín-Pérez, Sonia, Jiménez, Moraima, Dávila-Valls, Julio, Schönlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Imre Pinczés, László, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-Vélez, Irati, Fracchiolla, Nicola, Samarkos, Michail, Méndez, Gustavo-Adolfo, Hernández-Rivas, José-Ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, di Blasi, Roberta, Marques de Almedia, Joyce, Dargenio, Michelina, Biernat, Monika M., Sciumè, Mariarita, de Ramón, Cristina, de Jonge, Nick, Batinić, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández, Noemí, Zambrotta, Giovanni, Sacchi, Maria Vittoria, Guidetti, Anna, Demirkan, Fatih, Prezioso, Lucia, Ráčil, Zdeněk, Nucci, Marcio, Mladenović, Miloš, Liévin, Raphaël, Hanáková, Michaela, Gräfe, Stefanie, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adžić-Vukičević, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A.
- Published
- 2022
- Full Text
- View/download PDF
9. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO
- Author
-
Bailén, Rebeca, Iacoboni, Gloria, Delgado, Javier, López-Corral, Lucía, Hernani-Morales, Rafael, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Guerra-Domínguez, María Luisa, Sánchez-Pina, Jose Maria, Peña, Marta, Torrent, Anna, Pérez-Martínez, Antonio, Bastos-Oreiro, Mariana, Reguera-Ortega, Juan Luis, Martín, Alejandro, Hernandez-Boluda, Juan Carlos, Martínez-Cibrián, Nuria, Sanz, Jaime, Briones, Javier, Henriquez, Hugo Luzardo, Calbacho, María, Mussetti, Alberto, Sancho, Juan Manuel, Barba, Pere, and Kwon, Mi
- Published
- 2024
- Full Text
- View/download PDF
10. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
- Author
-
Kwon, Mi, Gómez-Centurión, Ignacio, Oarbeascoa, Gillen, Torres, Melissa, Martinez, Ariadna Perez, Suarez-Lledó, Maria, Chinea, Anabelle, Cascón, Maria Jesus Pascual, Vazquez, Lourdes, Espigado, Ildefonso, Izquierdo, Isabel, Parody, Rocio, Cadenas, Irene Garcia, Calbacho, Maria, Sierra, Pedro Gonzalez, Heras, Inmaculada, Yañez, Lucrecia, Torrent, Anna, Bautista, Guiomar, Gonzalez, Soledad, Roldan, Elisa, Vallejo, Juan Carlos, Bailen, Rebeca, Borrero, Asunción, Lopez-Jiménez, Javier, Casas, Maria Angeles Cuesta, and Solano, Carlos
- Published
- 2024
- Full Text
- View/download PDF
11. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain
- Author
-
Ribera, Josep-Maria, Morgades, Mireia, Coll, Rosa, Barba, Pere, López-Lorenzo, Jose-Luis, Montesinos, Pau, Foncillas, María-Angeles, Cabrero, Mónica, Gómez-Centurión, Ignacio, Morales, María-Dolores, Varela, María-Rosario, Herrera, Pilar, García-Cadenas, Irene, Calbacho, María, Torrent, Anna, Maluquer, Clara, Calabuig, Marisa, Garcia-Guiñon, Antoni, Bautista, Guiomar, Llorente, Laura, Gil, Cristina, Artola, María-Teresa, González-Campos, José, Fernández-Moreno, Ainhoa, Bárez, Abelardo, Giménez-Pérez, Teresa, Bergua, Juan, Sánchez-Sánchez, María-José, Mateos, María-Carmen, and Piñana, José-Luis
- Published
- 2021
- Full Text
- View/download PDF
12. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
- Author
-
Ribera, Josep-Maria, Morgades, Mireia, Ciudad, Juana, Montesinos, Pau, Esteve, Jordi, Genescà, Eulàlia, Barba, Pere, Ribera, Jordi, García-Cadenas, Irene, Moreno, María José, Martínez-Carballeira, Daniel, Torrent, Anna, Martínez-Sánchez, Pilar, Monsalvo, Silvia, Gil, Cristina, Tormo, Mar, Artola, María Teresa, Cervera, Marta, González-Campos, José, Rodríguez, Carlos, Bermúdez, Arancha, Novo, Andrés, Soria, Beatriz, Coll, Rosa, Amigo, María-Luz, López-Martínez, Aurelio, Fernández-Martín, Rosa, Serrano, Josefina, Mercadal, Santiago, Cladera, Antònia, Giménez-Conca, Alberto, Peñarrubia, María-Jesús, Abella, Eugènia, Vall-llovera, Ferran, Hernández-Rivas, Jesús-María, Garcia-Guiñon, Antoni, Bergua, Juan-Miguel, de Rueda, Beatriz, Sánchez-Sánchez, María-José, Serrano, Alfons, Calbacho, María, Alonso, Natalia, Méndez-Sánchez, Jose-Ángel, García-Boyero, Raimundo, Olivares, Matxalen, Barrena, Susana, Zamora, Lurdes, Granada, Isabel, Lhermitte, Ludovic, Feliu, Evarist, and Orfao, Alberto
- Published
- 2021
- Full Text
- View/download PDF
13. Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients.
- Author
-
Mingot-Castellano, Maria-Eva, Reguera-Ortega, Juan Luis, Zafra Torres, Denis, Hernani, Rafael, Lopez-Godino, Oriana, Guerreiro, Manuel, Herrero, Blanca, López-Corral, Lucia, Luna, Alejandro, Gonzalez-Pinedo, Lesli, Chinea-Rodriguez, Anabelle, Africa-Martín, Ana, Bailen, Rebeca, Martinez-Cibrian, Nuria, Balsalobre, Pascual, Filaferro, Silvia, Alonso-Saladrigues, Anna, Barba, Pere, Perez-Martinez, Antonio, and Calbacho, María
- Subjects
RED blood cell transfusion ,THROMBOPOIETIN receptor agonists ,BLOOD platelet transfusion ,ERYTHROCYTES ,CELL transplantation - Abstract
Background/Objectives: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully in patients with bone marrow failure and immune thrombocytopenia (ITP). Its role in managing thrombocytopenia and other cytopenias in CAR-T cell-treated patients has been scarcely addressed. Our aim was to report the safety and efficacy of this approach in patients included in the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC) registry. Methods: This is a retrospective, multicenter, observational study. Patients who developed platelet transfusion dependence subsequently to CAR-T cells and received eltrombopag to improve platelet counts were recruited in 10 Spanish hospitals. Results: Thirty-eight patients were enrolled and followed up for a median (interquartile range [IQR]) of 175 (99, 489) days since CAR-T cell infusion. At the moment eltrombopag was indicated, 18 patients had thrombocytopenia and another severe cytopenia, while 8 patients had severe pancytopenia. After 32 (14, 38) days on eltrombopag, 29 (76.3%) patients recovered platelet transfusion independence. The number of platelet units transfused correlated with the time needed to restore platelet counts higher than 20 × 10
9 /L (Rho = 0.639, p < 0.001). Non-responders to eltrombopag required more platelet units (58 [29, 69] vs. 12 [6, 26] in responders, p = 0.002). Nineteen out of twenty-three (82.6%) patients recovered from severe neutropenia after 22 (11, 31) days on eltrombopag. Twenty-nine out of thirty-five (82.9%) patients recovered red blood cell (RBC) transfusion independence after 29 (17, 44) days. Seven patients recovered all cell lineages while on treatment. No thromboembolic events were reported. Only two transient toxicities (cholestasis, hyperbilirubinemia) were reported during eltrombopag treatment, none of which compelled permanent drug withdrawal. Conclusions: Eltrombopag could be safely used to manage thrombocytopenia and accelerate transfusion independence in CAR-T cell-treated patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
- Author
-
Jiménez-Ubieto, Ana, primary, Martín-Muñoz, Alejandro, additional, Poza, María, additional, Dorado, Sara, additional, García-Ortiz, Almudena, additional, Revilla, Enrique, additional, Sarandeses, Pilar, additional, Ruiz-Heredia, Yanira, additional, Baumann, Tycho, additional, Rodríguez, Antonia, additional, Calbacho, María, additional, Sánchez, Pilar Martínez, additional, Pina, José María Sánchez, additional, García-Sancho, Alejandro Martín, additional, Figaredo, Gloria, additional, Gil-Alós, Daniel, additional, Rufián, Laura, additional, Rodríguez, Margarita, additional, Carneros, Laura, additional, Martínez-Laperche, Carolina, additional, Bastos-Oreiro, Mariana, additional, Wang, Chongwu, additional, Cedena, María-Teresa, additional, Rapado, Inmaculada, additional, de Toledo, Paula, additional, Gallardo, Miguel, additional, Valeri, Antonio, additional, Ayala, Rosa, additional, Martínez-López, Joaquín, additional, and Barrio, Santiago, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55–65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
- Author
-
Ribera, Josep-Maria, García, Olga, Gil, Cristina, Mercadal, Santiago, García-Cadenas, Irene, Montesinos, Pau, Barba, Pere, Vives, Susana, González-Campos, José, Tormo, Mar, Esteve, Jordi, López, Aurelio, Moreno, María José, Ribera, Jordi, Alonso, Natalia, Bermúdez, Arancha, Amigo, María Luz, Genescà, Eulàlia, García, Daniel, Vall-Llovera, Ferran, Bergua, Juan Miguel, Guàrdia, Ramon, Monteserín, María Carmen, Bernal, Teresa, Calbacho, María, Martínez, María Pilar, and Feliu, Evarist
- Published
- 2018
- Full Text
- View/download PDF
16. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
- Author
-
Jiménez-Ubieto, Ana, primary, Martín-Muñoz, Alejandro, additional, Poza, María, additional, Dorado, Sara, additional, García-Ortiz, Almudena, additional, Revilla, Enrique, additional, Sarandeses, Pilar, additional, Ruiz-Heredia, Yanira, additional, Baumann, Tycho, additional, Rodríguez, Antonia, additional, Calbacho, María, additional, Sánchez, Pilar Martínez, additional, Pina, José María Sánchez, additional, García-Sancho, Alejandro Martín, additional, Figaredo, Gloria, additional, Rufián, Laura, additional, Rodríguez, Margarita, additional, Carneros, Laura, additional, Martínez-Laperche, Carolina, additional, Bastos-Oreiro, Mariana, additional, Wang, Chongwu, additional, Cedena, María-Teresa, additional, Rapado, Inmaculada, additional, de Toledo, Paula, additional, Gallardo, Miguel, additional, Valeri, Antonio, additional, Ayala, Rosa, additional, Martínez-López, Joaquín, additional, and Barrio, Santiago, additional
- Published
- 2023
- Full Text
- View/download PDF
17. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
- Author
-
Kantarjian, Hagop M, DeAngelo, Daniel J, Advani, Anjali S, Stelljes, Matthias, Kebriaei, Partow, Cassaday, Ryan D, Merchant, Akil A, Fujishima, Naohito, Uchida, Toshiki, Calbacho, Maria, Ejduk, Anna A, O'Brien, Susan M, Jabbour, Elias J, Zhang, Hui, Sleight, Barbara J, Vandendries, Erik R, and Marks, David I
- Published
- 2017
- Full Text
- View/download PDF
18. Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
- Author
-
Bailén, Rebeca, primary, Alenda, Raquel, additional, Herruzo-Delgado, Beatriz, additional, Acosta-Fleitas, Cynthia, additional, Vallés, Ana, additional, Esquirol, Albert, additional, Fonseca, Marta, additional, Solán, Laura, additional, Sánchez-Vadillo, Irene, additional, Bautista, Guiomar, additional, Bento, Leyre, additional, López-Godino, Oriana, additional, Pérez-Martínez, Ariadna, additional, Torrent, Anna, additional, Zanabili, Joud, additional, Calbacho, María, additional, Moreno, Miguel Ángel, additional, Pascual-Cascón, María Jesús, additional, Guerra-Domínguez, Luisa, additional, Chinea, Anabelle, additional, García-Cadenas, Irene, additional, López-Corral, Lucía, additional, Boix-Giner, Francisco, additional, López Lorenzo, José Luis, additional, Humala, Karem, additional, Duarte, Rafael, additional, Sampol, Antonia, additional, Heras, Inmaculada, additional, Vicario, José Luis, additional, Balas, Antonio, additional, Oarbeascoa, Gillen, additional, Fernández-Caldas, Paula, additional, Anguita, Javier, additional, and Kwon, Mi, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group
- Author
-
Ribera, Josep-Maria, García, Olga, Oriol, Albert, Gil, Cristina, Montesinos, Pau, Bernal, Teresa, González-Campos, José, Lavilla, Esperanza, Ribera, Jordi, Brunet, Salut, Martínez, María-Pilar, Tormo, Mar, Genescà, Eulàlia, Barba, Pere, Sarrà, Josep, Monteserín, María-Carmen, Soria, Beatriz, Colorado, Mercedes, Cladera, Antònia, García-Guiñón, Antoni, Calbacho, María, Serrano, Alfons, Ortín, Xavier, Pedreño, María, Amigo, Maria-Luz, Escoda, Lourdes, and Feliu, Evarist
- Published
- 2016
- Full Text
- View/download PDF
20. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
- Author
-
Jiménez-Ubieto, Ana, Martín-Muñoz, Alejandro, Poza, María, Dorado, Sara, García-Ortiz, Almudena, Revilla, Enrique, Sarandeses, Pilar, Ruiz-Heredia, Yanira, Baumann, Tycho, Rodríguez, Antonia, Calbacho, María, Sánchez, Pilar Martínez, Pina, José María Sánchez, García-Sancho, Alejandro Martín, Figaredo, Gloria, Rufián, Laura, Rodríguez, Margarita, Carneros, Laura, Martínez-Laperche, Carolina, Bastos-Oreiro, Mariana, Wang, Chongwu, Cedena, María-Teresa, Rapado, Inmaculada, de Toledo, Paula, Valeri, Antonio, Ayala, Rosa, Martínez-López, Joaquín, and Barrio, Santiago
- Subjects
Immunology ,Immunology and Allergy - Published
- 2023
- Full Text
- View/download PDF
21. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
- Author
-
Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, Generalitat de Catalunya, Kwon, Mi, Iacoboni, Gloria, Reguera-Ortega, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Guerra Domínguez, María Luisa, Sánchez-Pina, José María, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailen, Rebeca, Carpio, Cecilia, Ribera, Josep-Maria, Sureda, Anna, Briones, Javier, Hernández-Boluda, Juan Carlos, Martínez-Cibrián, Nuria, Diez-Martin, José L., Jiménez Martín, Alejandro, Barba, Pere, Instituto de Salud Carlos III, Asociación Española Contra el Cáncer, Generalitat de Catalunya, Kwon, Mi, Iacoboni, Gloria, Reguera-Ortega, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Guerra Domínguez, María Luisa, Sánchez-Pina, José María, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailen, Rebeca, Carpio, Cecilia, Ribera, Josep-Maria, Sureda, Anna, Briones, Javier, Hernández-Boluda, Juan Carlos, Martínez-Cibrián, Nuria, Diez-Martin, José L., Jiménez Martín, Alejandro, and Barba, Pere
- Abstract
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P<0.001, respectively). Infections in the first 6 months post-infusion were also more common in patients treated with axi-cel (38% vs. 25%, P=0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P=0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P=0.195), 51% and 47% (P=0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG ≥2 and progressive disease before lymphodepletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those receiving tisa-cel. Efficacy was not significantly different between both products.
- Published
- 2023
22. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
- Author
-
Gilead Sciences, Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Gomes-Silva, Maria, Fracchiolla, Nicola S., Jonge, Nick de, Collins, Graham P., Marchetti, Monia, Magliano, Gabriel, García-Vidal, Carolina, Biernat, Monika, Doesum, Jaap van, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamin, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Príncipe, María Ilaria del, Cabirta, Alba, Ormazabal-Vélez, Irati, Jakšić, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Praet, Jens van, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin G., Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, Ramón, Cristina de, Cattaneo, Chiara, Calbacho, María, Bahr, Nathan C., El-Ashwah, Shaimaa, Córdoba, Raúl, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Nunes-Rodrigues, Raquel, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Gomes-Silva, Maria, Fracchiolla, Nicola S., Jonge, Nick de, Collins, Graham P., Marchetti, Monia, Magliano, Gabriel, García-Vidal, Carolina, Biernat, Monika, Doesum, Jaap van, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamin, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Príncipe, María Ilaria del, Cabirta, Alba, Ormazabal-Vélez, Irati, Jakšić, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Praet, Jens van, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin G., Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, Ramón, Cristina de, Cattaneo, Chiara, Calbacho, María, Bahr, Nathan C., El-Ashwah, Shaimaa, Córdoba, Raúl, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Nunes-Rodrigues, Raquel, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., and Pagano, Livio
- Abstract
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p<0.001). Overall survival in patients with COVID-19 diagnosis between January 2020 and August 2020 was significantly lower than those who were diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs 60% vs 61.9%, respectively; p=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
- Published
- 2023
23. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
- Author
-
Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, Cornely, Oliver A., Gilead Sciences, Salmanton-García, Jon, Marchesi, Francesco, Koehler, Philipp, Weinbergerová, Barbora, Čolović, Natasa, Falces-Romero, Iker, Buquicchio, Caterina, Farina, Francesca, Praet, Jens van, Biernat, Monika M., Itri, Federico, Prezioso, Lucia, Tascini, Carlo, Vena, Antonio, Romano, Alessandra, Delia, Mario, Dávila-Valls, Julio, Martín-Pérez, Sonia, Lavilla-Rubira, Esperanza, Adžić-vukičević, Tatjana, García-Bordallo, Daniel, López-García, Alberto, Criscuolo, Mariana, Petzer, Verena, Fracchiolla, Nicola S., Espigado, Ildefonso, Sili, Uluhan, Meers, Stef, Erben, Nurettin, Cattaneo, Chiara, Tragiannidis, Athanasios, Gavriilaki, Eleni, Schönlein, Martin, Mitrovic, Mirjana, Pantic, Nikola, Merelli, Maria, Labrador, Jorge, Hernández-Rivas, José Ángel, Glenthøj, Andreas, Fouquet, Guillemette, Príncipe, María Ilaria del, Dargenio, Michelina, Calbacho, María, Besson, Caroline, Kohn, Milena, Gräfe, Stefanie, Hersby, Ditte Stampe, Arellano-Orden, Elena, Çolak, Gökçe Melis, Wolf, Dominik, Marchetti, Monia, Nordlander, Anna, Blennow, Ola, Córdoba, Raúl, Mišković, Bojana, Mladenović, Miloš, Bavastro, Martina, Limongelli, Alessandro, Rahimli, Laman, Pagano, Livio, and Cornely, Oliver A.
- Abstract
[Introduction] Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications. A caveat for molnupiravir is the mode of action induces viral mutations. Mortality rate reduction with molnupiravir was less pronounced than that with nirmatrelvir/ritonavir in patients without haematological malignancy. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, molnupiravir and nirmatrelvir/ritonavir were compared in a cohort of patients with haematological malignancies., [Methods] Clinical data from patients treated with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and severity of baseline haematological malignancy to controls treated with nirmatrelvir/ritonavir., [Results] A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (interquartile range [IQR] 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 56.9% (n=66) of the patients had controlled baseline haematological malignancy, 12.9% (n=15) had stable disease, and 30.2% (n=35) had active disease at COVID-19 onset in each group. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of patients in the two groups were vaccinated (molnupiravir n=77, 66% vs. nirmatrelvir/ritonavir n=87, 75%), more of those treated with nirmatrelvir/ritonavir had received four vaccine doses (n=27, 23%) compared with those treated with molnupiravir (n=5, 4%) (P<0.001). No differences were detected in COVID-19 severity (P=0.39) or hospitalisation (P=1.0). No statistically significant differences were identified in overall mortality rate (P=0.78) or survival probability (d30 P=0.19, d60 P=0.67, d90 P=0.68, last day of follow up P=0.68). Deaths were either attributed to COVID-19, or the infection was judged by the treating physician to have contributed to death., [Conclusions] Hospitalisation and mortality rates with molnupiravir were comparable to those with nirmatrelvir/ritonavir in high-risk patients with haematological malignancies and COVID-19. Molnupiravir is a plausible alternative to nirmatrelvir/ritonavir for COVID-19 treatment in patients with haematological malignancy.
- Published
- 2023
24. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
- Author
-
Doesum, Jaap van, Salmanton-García, Jon, Marchesi, Francesco, Blasi, Roberta di, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Praet, Jens van, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, Ramón, Cristina de, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almedia, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin G., Hernández-Rivas, José Ángel, Gomes Da Silva, María, Fernández, Noemí, Espigado, Ildefonso, Drgona, Lubos, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, María, Blennow, Ola, Wolf, Dominik, Anrooij, Bjorn van, Nunes-Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Lievin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie, García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, Meerten, Tom van, Cornely, Oliver A., Pagano, Livio, Doesum, Jaap van, Salmanton-García, Jon, Marchesi, Francesco, Blasi, Roberta di, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Praet, Jens van, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, Ramón, Cristina de, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almedia, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin G., Hernández-Rivas, José Ángel, Gomes Da Silva, María, Fernández, Noemí, Espigado, Ildefonso, Drgona, Lubos, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, María, Blennow, Ola, Wolf, Dominik, Anrooij, Bjorn van, Nunes-Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Lievin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie, García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, Meerten, Tom van, Cornely, Oliver A., and Pagano, Livio
- Abstract
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
- Published
- 2023
25. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
- Author
-
Jiménez-Ubieto, Ana, Martín-Muñoz, Alejandro, Poza, María, Dorado, Sara, García-Ortiz, Almudena, Revilla, Enrique, Sarandeses, Pilar, Ruiz-Heredia, Yanira, Baumann, Tycho, Rodríguez, Antonia, Calbacho, María, Martínez Sánchez, Pilar, Sánchez Pina, José María, García-Sancho, Alejandro Martín, Figaredo, Gloria, Rufián, Laura, Rodríguez, Margarita, Carneros, Laura, Martínez-Laperche, Carolina, and Bastos-Oreiro, Mariana
- Subjects
CIRCULATING tumor DNA ,CHIMERIC antigen receptors ,FOLLICULAR lymphoma ,SOMATIC mutation ,T cells - Abstract
Background: CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores the potential value of ctDNA monitoring with an innovative signature of personalized trackable mutations. Method: Eleven FL patients treated with anti-CD19 CAR T-cell therapy were included. One did not respond and was excluded. Genomic profiling was performed before starting lymphodepleting chemotherapy to identify somatic mutations suitable for LiqBio-MRD monitoring. The dynamics of the baseline mutations (4.5 per patient) were further analyzed on 59 cfDNA follow-up samples. PET/CT examinations were performed on days +90, +180, +365, and every six months until disease progression or death. Results: After a median follow-up of 36 months, all patients achieved a CR as the best response. Two patients progressed. The most frequently mutated genes were CREBBP, KMT2D and EP300. Simultaneous analysis of ctDNA and PET/CT was available for 18 time-points. When PET/CT was positive, two out of four ctDNA samples were LiqBio-MRD negative. These two negative samples corresponded to women with a unique mesenteric mass in two evaluations and never relapsed. Meanwhile, 14 PET/CT negative images were mutation-free based on our LiqBio-MRD analysis (100%). None of the patients had a negative LiqBio-MRD test by day +7. Interestingly, all durably responding patients had undetectable ctDNA at or around three months after infusion. Two patients presented discordant results by PET/CT and ctDNA levels. No progression was confirmed in these cases. All the progressing patients were LiqBio-MRD positive before progression. Conclusion: This is a proof-of-principle for using ctDNA to monitor response to CAR T-cell therapy in FL. Our results confirm that a non-invasive liquid biopsy MRD analysis may correlate with response and could be used to monitor response. Harmonized definitions of ctDNA molecular response and pinpointing the optimal timing for assessing ctDNA responses are necessary for this setting. If using ctDNA analysis, we suggest restricting follow-up PET/CT in CR patients to a clinical suspicion of relapse, to avoid false-positive results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
- Author
-
Ayala, Rosa, primary, Carreño-Tarragona, Gonzalo, additional, Barragán, Eva, additional, Boluda, Blanca, additional, Larráyoz, María J., additional, Chillón, María Carmen, additional, Carrillo-Cruz, Estrella, additional, Bilbao, Cristina, additional, Sánchez-García, Joaquín, additional, Bernal, Teresa, additional, Martinez-Cuadron, David, additional, Gil, Cristina, additional, Serrano, Josefina, additional, Rodriguez-Medina, Carlos, additional, Bergua, Juan, additional, Pérez-Simón, José A., additional, Calbacho, María, additional, Alonso-Domínguez, Juan M., additional, Labrador, Jorge, additional, Tormo, Mar, additional, Amigo, Maria Luz, additional, Herrera-Puente, Pilar, additional, Rapado, Inmaculada, additional, Sargas, Claudia, additional, Vazquez, Iria, additional, Calasanz, María J., additional, Gomez-Casares, Teresa, additional, García-Sanz, Ramón, additional, Sanz, Miguel A., additional, Martínez-López, Joaquín, additional, and Montesinos, Pau, additional
- Published
- 2022
- Full Text
- View/download PDF
27. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, and Batinić, Josip
- Abstract
Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However
- Published
- 2021
28. P-113: Infectious toxicities in patients treated with bispecific antibodies in multiple myeloma
- Author
-
Saez, Adolfo, primary, Lopez-Muñoz, Nieves, additional, Sánchez-Pina, José María, additional, Alonso, Rafael, additional, cuellar, Clara, additional, lázaro, Paula, additional, Ubieto, Ana Jiménez, additional, Calbacho, María, additional, and López, Joaquín Martinez, additional
- Published
- 2022
- Full Text
- View/download PDF
29. Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)
- Author
-
Fox, María Laura, Cabirta, Alba, Pérez Martínez, Ariadna, Esquirol, Albert, Fonseca, Marta, Navarro Garcés, Víctor, Heras, Inmaculada, Bento, Leyre, Calo Pérez, Aida, Zudaire, Teresa, Calbacho, Maria, Gago, Beatriz, Pérez, Ana, Ortí, Guillermo, García-Cadenas, Irene, Corral, Lucía López, Navarro-Fernández, José, Montoro Gomez, Juan, Sampol, Antonia, Solano, Carlos, and Valcarcel, David
- Published
- 2022
- Full Text
- View/download PDF
30. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts
- Author
-
Font, Patricia, Loscertales, Javier, Soto, Carlos, Ricard, Pilar, Novas, Carolina Muñoz-, Martín-Clavero, Estela, López-Rubio, Montserrat, Garcia-Alonso, Luis, Callejas, Marta, Bermejo, Alfredo, Benavente, Celina, Ballesteros, Mónica, Cedena, Teresa, Calbacho, María, Urbina, Raquel, Villarrubia, Jesús, Gil, Santiago, Bellón, José María, Diez-Martin, José Luis, and Villegas, Ana
- Published
- 2015
- Full Text
- View/download PDF
31. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
- Author
-
Kwon, Mi, primary, Iacoboni, Gloria, additional, Reguera, Juan Luis, additional, Corral, Lucía López, additional, Morales, Rafael Hernani, additional, Ortiz-Maldonado, Valentín, additional, Guerreiro, Manuel, additional, Caballero, Ana Carolina, additional, Domínguez, María Luisa Guerra, additional, Pina, Jose Maria Sanchez, additional, Mussetti, Alberto, additional, Sancho, Juan Manuel, additional, Bastos-Oreiro, Mariana, additional, Catala, Eva, additional, Delgado, Javier, additional, Henriquez, Hugo Luzardo, additional, Sanz, Jaime, additional, Calbacho, María, additional, Bailén, Rebeca, additional, Carpio, Cecilia, additional, Ribera, Jose Maria, additional, Sureda, Anna, additional, Briones, Javier, additional, Hernandez-Boluda, Juan Carlos, additional, Cebrián, Nuria Martínez, additional, Martin, Jose Luis Diez, additional, Martín, Alejandro, additional, and Barba, Pere, additional
- Published
- 2022
- Full Text
- View/download PDF
32. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
- Author
-
Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, López-García, Alberto, Lamure, Sylvain, Itri, Federico, Gomes-Silva, Maria, Dragonetti, Giulia, Falces-Romero, Iker, van Doesum, Jaap, Sili, Uluhan, Labrador, Jorge, Calbacho, Maria, Bilgin, Yavuz M., Weinbergerová, Barbora, Serrano, Laura, Ribera-Santa Susana, José-María, Malak, Sandra, Loureiro-Amigo, José, Glenthøj, Andreas, Córdoba-Mascuñano, Raúl, Nunes-Rodrigues, Raquel, González-López, Tomás-José, Karlsson, Linda Katharina, Jiménez-Lorenzo, María-Josefa, Hernández-Rivas, José-Ángel, Jaksic, Ozren, Ráčil, Zdeněk, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, and Cornely, Oliver A.
- Published
- 2022
- Full Text
- View/download PDF
33. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
- Author
-
Ayala Díaz, Rosa María, Carreño Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María J., Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sánchez García, Joaquín, Bernal, Teresa, Martínez Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez Medina, Carlos, Bergua, Juan, Pérez Simón, José A., Calbacho, María, Alonso Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, Maria Luz, Herrera Puente, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, María J., Gómez Casares, Teresa, García Sanz, Ramón, Sanz, Miguel A., Martínez López, Joaquín, Montesinos, Pau, Ayala Díaz, Rosa María, Carreño Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María J., Chillón, María Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sánchez García, Joaquín, Bernal, Teresa, Martínez Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez Medina, Carlos, Bergua, Juan, Pérez Simón, José A., Calbacho, María, Alonso Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, Maria Luz, Herrera Puente, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, María J., Gómez Casares, Teresa, García Sanz, Ramón, Sanz, Miguel A., Martínez López, Joaquín, and Montesinos, Pau
- Abstract
FLT3–ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3–ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3–ITD mutations. In multivariate analyses, patients with an FLT3–ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3–ITD-mutated patients, median OS gradually decreased according to FLT3–ITD status and ratio (34.3 months FLT3–ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3–ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3–ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3–ITD status in all patients, and we found that the group of FLT3–ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3–ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3–ITD mutations., Instituto de Salud Carlos III, Fundación CRIS Contra el Cáncer, Instituto de Investigación Hospital 12 de Octubre, Unión Europea, Depto. de Medicina, Fac. de Medicina, TRUE, pub
- Published
- 2022
34. Programa de motricidad globalizada en Infantil en Ghana
- Author
-
Díaz Calbacho, María, López Pastor, Víctor Manuel, Molina Soria, Miriam, Díaz Calbacho, María, López Pastor, Víctor Manuel, and Molina Soria, Miriam
- Abstract
El siguiente Trabajo de Fin de Grado es una propuesta de motricidad basada principalmente en la idea del aprendizaje globalizado partiendo del cuerpo y el movimiento del niño en la etapa de Educación Infantil. La propuesta de motricidad diseñada y programada en mi TFG la conforman cuarenta cuñas motrices, cuatro sesiones de cuentos motores y ocho de canciones motrices, que se han llevado a cabo en una escuela pública situada en una zona rural del noroeste de Ghana: Wulugu Primary School (Larabanga). Se ha llevado a cabo una evaluación formativa del alumnado y de la propia maestra a través de diferentes instrumentos de evaluación. Los principales resultados obtenidos son el gran desarrollo motor de los niños y sus altas capacidades físicas, frente a la falta de colaboración y respeto entre iguales que dificultan el buen clima de aula., Grado en Educación Infantil
- Published
- 2022
35. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
- Author
-
Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Instituto de Investigación Hospital 12 de Octubre, Ayala Bueno, Rosa, Carreño-Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sanchez-Garcia, Joaquin, Bernal, T., Martínez-Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez-Medina, Carlos, Bergua, Juan, Pérez-Simón, José A., Calbacho, María, Alonso-Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, María Luz, Herrera, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, Mª Jose, Gómez-Casares, M. T., García-Sanz, Ramón, Sanz, Miguel Ángel, Martínez-López, Joaquín, Montesinos, Pau, Instituto de Salud Carlos III, Fundación CRIS contra el Cáncer, Instituto de Investigación Hospital 12 de Octubre, Ayala Bueno, Rosa, Carreño-Tarragona, Gonzalo, Barragán, Eva, Boluda, Blanca, Larráyoz, María José, Chillón, M. del Carmen, Carrillo Cruz, Estrella, Bilbao, Cristina, Sanchez-Garcia, Joaquin, Bernal, T., Martínez-Cuadrón, David, Gil, Cristina, Serrano, Josefina, Rodríguez-Medina, Carlos, Bergua, Juan, Pérez-Simón, José A., Calbacho, María, Alonso-Domínguez, Juan Manuel, Labrador, Jorge, Tormo, Mar, Amigo, María Luz, Herrera, Pilar, Rapado, Inmaculada, Sargas, Claudia, Vázquez, Iria, Calasanz, Mª Jose, Gómez-Casares, M. T., García-Sanz, Ramón, Sanz, Miguel Ángel, Martínez-López, Joaquín, and Montesinos, Pau
- Abstract
FLT3–ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3–ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3–ITD mutations. In multivariate analyses, patients with an FLT3–ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3–ITD-mutated patients, median OS gradually decreased according to FLT3–ITD status and ratio (34.3 months FLT3–ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3–ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3–ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3–ITD status in all patients, and we found that the group of FLT3–ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3–ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3–ITD mutations.
- Published
- 2022
36. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
- Author
-
Gilead Sciences, Infante, María-Stefania, Salmanton-García, Jon, Ana Fernández-Cruz, Marchesi, Francesco, Jakšić, Ozren, Weinbergerová, Barbora, Duarte, Rafael F., Itri, Federico, Valković, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthøj, Andrea, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Cengiz Seval, Guldane, Machado, Marina, Córdoba, Raúl, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin G., Falces-Romero, Iker, Cattaneo, Chiara, Doesum, Jaap van, Piukovics, Klára, Omrani, Ali S., Magliano, Gabriel, Ledoux, Marie-Pierre, Ramón, Cristina de, Cabirta, Alba, Verga, Luisa, López-García, Alberto, Gomes Da Silva, María, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martín-Pérez, Sonia, Dávila, Julio, Praet, Jens van, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinić, Josip, Nordlander, Anna, Schönlein, Martin, Hoenigl, Martin, Ráčil, Zdeněk, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni, Jonge, Nick de, Adžić-Vukičević, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navrátil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, María, Giordano, Antonio, Cornely, Oliver A., Hernández-Rivas, José Ángel, Pagano, Livio, Gilead Sciences, Infante, María-Stefania, Salmanton-García, Jon, Ana Fernández-Cruz, Marchesi, Francesco, Jakšić, Ozren, Weinbergerová, Barbora, Duarte, Rafael F., Itri, Federico, Valković, Toni, Szotkovski, Tomas, Busca, Alessandro, Guidetti, Anna, Glenthøj, Andrea, Collins, Graham P., Bonuomo, Valentina, Sili, Uluhan, Cengiz Seval, Guldane, Machado, Marina, Córdoba, Raúl, Blennow, Ola, Abu-Zeinah, Ghaith, Lamure, Sylvain, Kulasekararaj, Austin G., Falces-Romero, Iker, Cattaneo, Chiara, Doesum, Jaap van, Piukovics, Klára, Omrani, Ali S., Magliano, Gabriel, Ledoux, Marie-Pierre, Ramón, Cristina de, Cabirta, Alba, Verga, Luisa, López-García, Alberto, Gomes Da Silva, María, Stojanoski, Zlate, Meers, Stef, Lahmer, Tobias, Martín-Pérez, Sonia, Dávila, Julio, Praet, Jens van, Samarkos, Michail, Bilgin, Yavuz M., Karlsson, Linda Katharina, Batinić, Josip, Nordlander, Anna, Schönlein, Martin, Hoenigl, Martin, Ráčil, Zdeněk, Mladenovic, Milos, Hanakova, Michaela, Zambrotta, Giovanni, Jonge, Nick de, Adžić-Vukičević, Tatjana, Nunes-Rodrigues, Raquel, Prezioso, Lucia, Navrátil, Milan, Marchetti, Monia, Cuccaro, Annarosa, Calbacho, María, Giordano, Antonio, Cornely, Oliver A., Hernández-Rivas, José Ángel, and Pagano, Livio
- Abstract
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
- Published
- 2022
37. Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia
- Author
-
Martínez‑López, Joaquín, primary, Montesinos, Pau, additional, López‑Muñoz, Nieves, additional, Ayala, Rosa, additional, Martínez‑Sánchez, Pilar, additional, Gorrochategui, Julian, additional, Rojas‑Rudilla, José, additional, Primo, Daniel, additional, Bergua‑Burgues, Juan-Miguel, additional, Calbacho, María, additional, Acuña‑Cruz, Evelyn, additional, Pérez‑Simón, José, additional, De La Fuente, Adolfo, additional, Pérez De Oteyza, Jaime, additional, Rodriguez‑Veiga, Rebeca, additional, Pina, José, additional, Boluda, Blanca, additional, Cano, Isabel, additional, Paciello Coronel, María, additional, and Ballesteros, Juan, additional
- Published
- 2022
- Full Text
- View/download PDF
38. Use of eltrombopag after romiplostim in primary immune thrombocytopenia
- Author
-
González-Porras, José Ramón, Mingot-Castellano, María Eva, Andrade, Marcio M., Alonso, Rafael, Caparrós, Isabel, Arratibel, María Carmen, Fernández-Fuertes, Fernando, Cortti, Maria José, Pascual, Cristina, Sánchez-González, Blanca, Bernat, Silvia, Fuertes-Palacio, Miguel Angel, Vázquez-Paganini, Juan Andrés, Olivera, Pavel E., Alvarez-Román, María Teresa, Jarque, Isidro, Cortés, Montserrat, Martínez-Robles, Violeta, Díaz-Gálvez, Francisco Javier, Calbacho, María, Fernández-Miñano, Carmen, Garcia-Frade, Javier, and González-López, Tomás José
- Published
- 2015
- Full Text
- View/download PDF
39. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
- Author
-
González-López, Tomás José, Pascual, Cristina, Álvarez-Román, María Teresa, Fernández-Fuertes, Fernando, Sánchez-González, Blanca, Caparrós, Isabel, Jarque, Isidro, Mingot-Castellano, María Eva, Hernández-Rivas, José Angel, Martín-Salces, Mónica, Solán, Laura, Beneit, Paola, Jiménez, Reyes, Bernat, Silvia, Andrade, Marcio M., Cortés, Montserrat, Cortti, Maria José, Pérez-Crespo, Susana, Gómez-Núñez, Marta, Olivera, Pavel E., Pérez-Rus, Gloria, Martínez-Robles, Violeta, Alonso, Rafael, Fernández-Rodríguez, Angeles, Arratibel, María Carmen, Perera, María, Fernández-Miñano, Carmen, Fuertes-Palacio, Miguel Angel, Vázquez-Paganini, Juan Andrés, Gutierrez-Jomarrón, Isabel, Valcarce, Inés, de Cabo, Erik, Sainz, Adriana, Fisac, Rosa, Aguilar, Carlos, Paz Martínez-Badas, María, Peñarrubia, María Jesús, Calbacho, María, de Cos, Carmen, González-Silva, Manuel, Coria, Erika, Alonso, Arancha, Casaus, Alberto, Luaña, Armando, Galán, Pilar, Fernández-Canal, Cristina, Garcia-Frade, Javier, and González-Porras, José Ramón
- Published
- 2015
- Full Text
- View/download PDF
40. P-148: Real-life analysis of the multiple myeloma patient’s survival in a third-level hospital
- Author
-
López-Muñoz, Nieves, primary, García, Rodrigo Íñiguez, additional, Fernández, Rafael Alberto Alonso, additional, Sánchez-Pina, Jose M, additional, Cuéllar, Clara, additional, Ubieto, Ana Jiménez, additional, Calbacho, María, additional, Ayala, Rosa, additional, Paciello, M Liz, additional, Sánchez, M Pilar Martínez, additional, Guerrero, Elena Vera, additional, Soto, Marta Hidalgo, additional, Poza, María, additional, Zamanillo, Irene, additional, and Martínez-López, Joaquín, additional
- Published
- 2021
- Full Text
- View/download PDF
41. Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)
- Author
-
Fernandez-Luis, Sara, Bermudez, Arancha, Yanez San Segundo, Lucrecia, Baile González, Mónica, Marcos Asensio, Sara, Esquirol, Albert, García-Cadenas, Irene, Pascual, Maria Jesus, Herruzo, Beatriz, Salas, Maria Queralt, Alburquerque-Prieto, Cristina, Viguria-Alegría, MC, Perez, Ariadna, Hernani, Rafael, Jiménez Lorenzo, María-José, Villalba, Marta, Martin Calvo, Carmen, Fabbri, Nicole, Gonzalez, Ana Pilar, Bailen, Rebeca, Garcia, Lucia, García Mañó, Lucia, Torchia Esteban, Marcos, Calbacho, Maria, Bento De Miguel, Leyre, and Sureda Balari, Anna Maria
- Published
- 2023
- Full Text
- View/download PDF
42. Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial
- Author
-
Mosquera Orgueira, Adrian, Perez Encinas, Manuel, Diaz Arias, Jose Angel, Rodriguez Veiga, Rebeca, Bergua Burgues, Juan Miguel, Algarra, Lorenzo, Botella, Carmen, Perez Simon, Jose Antonio, Bernal, Teresa, Tormo, Mar, Calbacho, Maria, Salamero, Olga, Serrano, Josefina, Noriega, Victor, Lopez Lopez, Juan Antonio, Vives, Susana, Colorado, Mercedes, Lopez Lorenzo, Jose Luis, Vidriales Vicente, Maria, Garcia Boyero, Raimundo, Olave Rubio, Maria Teresa, Herrera Puente, Pilar, Arce, Olga, Barrios Garcia, Manuel, Sayas Lloris, Maria Jose, Polo, Marta, Gomez Roncero, Maria Isabel, Barragan, Eva, Ayala, Rosa, Chillon, Carmen, Calasanz, Maria Jose, Boluda, Blanca, Peleteiro Raindo, Andres, Amigo, Raquel, Labrador, Jorge, Martinez Cuadron, David, and Montesinos, Pau
- Published
- 2023
- Full Text
- View/download PDF
43. Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo
- Author
-
Bailen, Rebeca, Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Ortiz-Maldonado, Valentin, Guerreiro, Manuel, Caballero Gonzalez, Ana Carolina, Guerra, Luisa, Sanchez Pina, Jose Maria, Mussetti, Alberto, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Catalá, Eva, Delgado Serrano, Javier, Luzardo Henriquez, Hugo Daniel, Caballer, Jaime Sanz, Calbacho, Maria, Carpio, Cecilia, Ribera, Josep-Maria, Torrent, Anna, Sureda Balari, Anna Maria, Briones, Javier, Hernandez Boluda, Juan Carlos, Martinez-Cibrian, Nuria, Martin Garcia-Sancho, Alejandro, and Barba, Pere
- Published
- 2023
- Full Text
- View/download PDF
44. Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years
- Author
-
Sáez Marín, Adolfo Jesús, Hernández-Ibarburu, Gema, Alonso Fernández, Rafael, Sanchez Pina, Jose Maria, Lázaro Del Campo, Paula, Jimenez Ubieto, Ana, Cuellar, Clara, Tamayo Soto, Andrea, Mas Babio, Reyes, Medina, Lucia, Calbacho, Maria, Ayala, Rosa, and Martinez Lopez, Joaquin
- Published
- 2023
- Full Text
- View/download PDF
45. Trial in Progress: An Open Label Phase I/II, Multicenter Study Evaluating Safety, Pharmacokinetics and Efficacy of S65487, a BCL-2 Inhibitor Combined with Azacitidine in Adults with Previously Untreated Acute Myeloid Leukemia Ineligible for Intensive Treatment
- Author
-
Pierola, Ana Alfonso, De Botton, Stephane, Jang, Jun Ho, Campbell, Victoria, O'Nions, Jenny, Calbacho, Maria, Ervin-Haynes, Annette L., Keagle, Kristen, Maillard, Aline, Beneton, Maud, Romagnoli, Mathilde, and Broniscer, Alberto
- Published
- 2023
- Full Text
- View/download PDF
46. Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital
- Author
-
Jimenez Ubieto, Ana, Gil Manso, Rodrigo, Gil Alós, Daniel, Poza Santaella, María, Baumann, Tycho, Rodriguez Izquierdo, Antonia, Quesada Sánchez, Marina, Martinez Sanchez, Pilar, Grande, Carlos, Garcia Gigorro, Renata, Calbacho, Maria, Barrio, Santiago, and Martinez Lopez, Joaquin
- Published
- 2023
- Full Text
- View/download PDF
47. Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients
- Author
-
Poza Santaella, Maria, Íñiguez, Rodrigo, Zamanillo, Irene, Baumann, Tycho S., Rodriguez Izquierdo, Antonia, Revilla, Enrique, Gomez Rojas, Sandra, Perez Segura, Gloria, Martinez Sanchez, Pilar, Grande, Carlos, Sarandeses, Pilar, Barrio, Santiago, Calbacho, Maria, Ayala, Rosa, Martinez-Lopez, Joaquin, and Jimenez Ubieto, Ana
- Published
- 2023
- Full Text
- View/download PDF
48. The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial
- Author
-
Mosquera Orgueira, Adrian, Perez Encinas, Manuel, Diaz Arias, Jose Angel, Rodriguez Veiga, Rebeca, Bergua Burgues, Juan Miguel, Algarra, Jesús Lorenzo, Botella, Carmen, Perez Simon, Jose Antonio, Bernal, Teresa, Tormo, Mar, Calbacho, Maria, Salamero, Olga, Serrano, Josefina, Noriega, Victor, Lopez Lopez, Juan Antonio, Vives, Susana, Colorado, Mercedes, Lopez Lorenzo, Jose Luis, Vidriales Vicente, Maria, Garcia Boyero, Raimundo, Olave Rubio, Maria Teresa, Herrera Puente, Pilar, Arce, Olga, Barrios Garcia, Manuel, Sayas Lloris, Maria Jose, Polo, Marta, Gomez Roncero, Maria Isabel, Barragan, Eva, Ayala, Rosa, Chillon, Carmen, Calasanz, Maria Jose, Boluda, Blanca, Peleteiro Raindo, Andres, Amigo, Raquel, Martinez Cuadron, David, Labrador, Jorge, and Montesinos, Pau
- Published
- 2023
- Full Text
- View/download PDF
49. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
- Author
-
Bailén, Rebeca, primary, Vicario, José Luis, additional, Solán, Laura, additional, Sánchez-Vadillo, Irene, additional, Herrera, Pilar, additional, Calbacho, María, additional, Alenda, Raquel, additional, López-Lorenzo, José Luis, additional, Humala, Karem, additional, Chinea, Anabelle, additional, Sánchez-Pina, José, additional, Balas, Antonio, additional, Moreno, Miguel Ángel, additional, Arzuaga, Javier, additional, Pradillo, Virginia, additional, Dorado, Nieves, additional, Oarbeascoa, Gillen, additional, Anguita, Javier, additional, Díez-Martín, José Luis, additional, and Kwon, Mi, additional
- Published
- 2021
- Full Text
- View/download PDF
50. P-473 Real-world evidence of statins and oral antidiabetics for multiple myeloma
- Author
-
Lopez-Munoz, Nieves, Hernandez-Ibarburu, Gema, Sanchez, Jose Maria, Alonso, Rafael, Cuellar, Clara, Calbacho, Maria, Cedena, M Teresa, Jimenez-Ubieto, Ana, Ayala, Rosa, Meloni, Laura, Perez-Rey, David, and Martinez-Lopez, Joaquín
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.